Tafamidis

Tafamidis is the medicine inside Vyndamax and Vyndaqel. The US label describes it as a selective stabilizer of transthyretin, the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization. The atlas holds no trial results for it.

Also called Vyndamax · Vyndaqel

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 1545063. Two FDA applications: NDA212161 (Vyndamax, tafamidis) and NDA211996 (Vyndaqel, tafamidis meglumine, whose marketing status is discontinued in the Drugs@FDA record although the label record still names the brand). One label record, version 15, covers both brands. The mechanism comes from that label.

Trials at a glance

The figures count the 2 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
2
Phase 3 or 4
2
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedAll statuses
Phase 322
All phases22

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
A selective stabilizer of transthyretin (US drug label).

Claims and evidence

Context Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax

Recipient
Adult
Population
Adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), as the label states its indication.
Care setting
Prescription medicine taken by mouth; the label record states no care setting
Geography
United States (labeling approved by the US Food and Drug Administration)
Life stage
Adults
Follow-up
Not applicable (regulatory and labeling statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (label indication)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The openFDA records list two tafamidis applications, both with an original submission approved on 3 May 2019: NDA212161 for Vyndamax (tafamidis; class Type 2 - New Active Ingredient; applicant FOLDRX PHARMS), listed as a prescription product, and NDA211996 for Vyndaqel (tafamidis meglumine; class Type 1 - New Molecular Entity), listed as discontinued. One label record (version 15, effective 12 May 2026) still names both brands and says they are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Applies to Adult Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax

    Certainty method
    Not assessed
    Limitations
    An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The discontinued status of Vyndaqel is the marketing status in the openFDA application record, and the label record still lists the brand, so the two sources are given side by side without reconciling them. The two applications are for different forms of the substance (the meglumine salt and tafamidis itself). The label record is a copy and may not show later changes. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (14)
    1. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].application_number
      How it applies
      Application number of Vyndamax.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    2. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].sponsor_name
      How it applies
      Applicant.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    3. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].products[0].brand_name
      How it applies
      Brand name.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    4. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].products[0].active_ingredients[0].name
      How it applies
      Active ingredient.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    5. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].submissions[1].submission_status_date
      How it applies
      Date of the original approval, written as eight digits.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    6. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].submissions[1].submission_class_code_description
      How it applies
      Class of the original submission.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    7. Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA212161

      Locator
      results[0].products[0].marketing_status
      How it applies
      Marketing status of Vyndamax.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    8. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].application_number
      How it applies
      Application number of Vyndaqel.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    9. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].products[0].brand_name
      How it applies
      Brand name.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    10. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].products[0].active_ingredients[0].name
      How it applies
      Active ingredient.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    11. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].submissions[0].submission_status_date
      How it applies
      Date of the original approval, written as eight digits.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    12. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].submissions[0].submission_class_code_description
      How it applies
      Class of the original submission.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    13. Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA211996

      Locator
      results[0].products[0].marketing_status
      How it applies
      Marketing status of Vyndaqel.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    14. Supports Vyndaqel and Vyndamax drug label (openFDA record, set id 1b4121ee-a733-4456-a917-be2603477839)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label version 15, effective 20260512, dataset last updated 2026-10-30. One label covers both Vyndaqel and Vyndamax. · SPL set id: 1b4121ee-a733-4456-a917-be2603477839

      Locator
      results[0].indications_and_usage[0]
      How it applies
      Indication in the label record.
      Retrieved
      Source effective date
      2026-05-12
      Source state
      Current
      Version fingerprint
      bedf5f095796dfdac9f9344d3cc362424ca403537b52a20b748c8cda7b0eb226
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, https://open.fda.gov/license/; licence page fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

VYNDAMAX

No label from the application holder was found in the openFDA label dataset for application NDA212161. This page does not show another labeler's label in its place.

VYNDAQEL

No label from the application holder was found in the openFDA label dataset for application NDA211996. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA211996 VYNDAQEL
  2. Approval NDA212161 VYNDAMAX

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA211996

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA212161

Registry trials 2

Record details

Record id
cardio:tafamidis
Content hash
41621e727b1a3a4da5ae713b99fa1cba48d0bbc23344dd54f70ba372f7483478